A retrospective analysis of national administrative claims data published online published online Dec. 21, 2018 in JAMA Network Open has shown that among insured adult patients with type 2 diabetes initiating second-line antidiabetic medications, the short-term cardiovascular outcomes of GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors were similar. Higher cardiovascular risk was associated with use of sulfonylureas or basal insulin compared with newer ADM classes.  The study suggests that clinicians may consider prescribing GLP-1 receptor agonists, SGLT-2 inhibitors, or DPP-4 inhibitors more routinely after metformin rather than sulfonylureas or basal insulin.